A Dose of Clarity

As we close the chapter on month one of 2026, we’re seeing pharmacy benefit regulation, drug pricing oversight, and PBM reform...

If you’ve ever been through a pharmacy benefits Request for Proposal (RFP), you know the drill: hundreds of questions, dozens of spreadsheets, and weeks of waiting. Yet, after all that, the final decision still feels like a guess. It can feel like using last year’s grocery receipts to budget for this year’s prices. Bottom line? It’s an outdated process. The Cost of a Complicated Process Traditional RFPs were designed to standardize how organizations evaluate PBMs. On paper, t

As we wrap up 2025, the pharmacy benefit management (PBM) landscape is advancing rapidly. For brokers, employers, and third party administrators (TPAs), the key to staying ahead is recognizing not just traditional cost drivers but emerging disruptors: High-cost specialty and gene/cell therapies Global supply chain/tariff dynamics New regulatory pressure Rescription is built for the future of pharmacy benefits and this state-of-the-industry report outlines what matters now, an

Learn what to look for in a PBM partner, from transparency to aligned incentives, to protect your plan and build towards a long-term goal.

What does it really take to become an entrepreneur? According to Scott Martin ’90, it’s not just about ideas or ambition—it’s about grit, timing, hard work, and a bit of chaos. This spring, Martin returned to Hobart and William Smith Colleges as Entrepreneur in Residence, bringing with him decades of startup experience and real-world wisdom. Over a whirlwind three-day visit, he met with students, led classroom discussions, mentored finalists in the annual Pitch competition, a

At Rescription, we believe in the power of giving back to those who have given so much. That’s why we’re thrilled to announce that we are a proud sponsor of the Bob Woodruff Foundation and the upcoming Veterans Golf Classic in Nashville. This event is more than just a fundraiser—it’s a celebration of the strength, resilience, and sacrifices of our nation’s veterans.  A Legacy of Resilience and Service The Bob Woodruff Foundation was founded by ABC News correspondent Bob Woodr

At Rescription, we see firsthand how Pharmacy Benefit Managers (PBMs) affect the healthcare landscape—and it’s clear that reform is long overdue. Like Rep. Buddy Carter (R-GA), Sen. James Lankford (R-OK), Rep. Nanette Barragan (D-CA), and other bipartisan lawmakers who have recently rallied for PBM reform, we believe that addressing the inefficiencies and profit-driven practices of PBMs is critical for creating a more transparent, affordable, and patient-centered healthcare s

Rescription, the Anti-PBM solution, is pleased to announce a new partnership with Howden Re, the premier reinsurance broker and advisor for the global market. Through the agreement, both new and existing Howden Re clients will be provided access to substantial savings on the high-cost and specialty drugs that average 70% plus of an employer's total cost. In addition, clients of both companies will benefit from more competitive reinsurance rates due to guaranteed published pri

As the season for PBM (Pharmacy Benefit Manager) renewals and evaluations arrives, a familiar sense of unease looms over employers' desks. Each year, net costs surge at an unsustainable pace, casting a shadow of concern over companies. Do you ever find yourself exasperated by the constant assurance of higher rebates, only to witness your expenses rise in tandem, leaving your bottom line untouched? If so, Rescription stands apart by honing in on top-line cost management – the

In an era where employer health and benefit costs are on the rise, the importance of reevaluating benefit offerings has never been clearer. With the looming prospect of escalating costs, employers are seeking comprehensive solutions that go beyond mere integration of disparate point solutions, aiming for enhanced ROI and employee satisfaction. Effective cost containment strategies stand as a pivotal complement to comprehensive benefits solutions. As employers navigate the lan

One of the biggest health insurers in the country, Blue Shield of California, has decided to drop CVS Health’s Caremark as their pharmacy benefit manager. This has "sent jitters through Wall Street," as reflected by the drop in each of the PBM Big Three’s (CVS, Cigna, and UnitedHealth) stock prices. Rather than working with Caremark, Blue Shield has decided to use Amazon, Mark Cuban’s Cost Plus, and several others to manage prescription drug costs in a way that is different f

A PBM is a third-party entity that operates as an intermediary between health insurance plans, pharmacies, and prescription drug manufacturers. The primary objective of PBMs is to streamline the prescription drug distribution process, enhance cost-effectiveness, and ensure that patients have access to necessary medications. They negotiate contracts with drug manufacturers, establish drug formularies, process prescription claims, and administer pharmacy networks for health ins

In the realm of prescription drug pricing transparency, the utilization of NADAC (National Average Drug Acquisition Cost) pricing shines as a superior alternative to the commonly employed AWP (Average Wholesale Price) pricing model. NADAC pricing offers distinct benefits that foster a clearer understanding of medication costs for both healthcare providers and patients. NADAC pricing stands out due to its inherent transparency. Unlike AWP, NADAC prices are publicly accessible

(Paramus, NJ) – Bergen New Bridge Medical Center has partnered with Rescription, a Pharmacy Benefit Manager (PBM) replacement company that offers a more cost-effective medication option. This affordable and simple prescription drug model provides employers, their employees, and their families with a significant reduction in their prescription drug costs. On average, employers who utilize Rescription’s model are experiencing 25%-35% overall net savings by moving away from thei

Weight loss drugs are no doubt trending, and they may be the answer for a growing number of people struggling with their weight, but the costs are high for self-insured employers. According to the Centers for Disease Control and Prevention, about 74 percent of adults in the United States are overweight and some may be turning to the popular drug Ozempic, an FDA-approved prescription medication for people with type 2 diabetes. Although unofficially termed “weight loss drugs,”